4
Changes in Ownership
Nurix Therapeutics, Inc. Filed Acc 0001549595-24-000106
Chief Scientific Officer sold 3,408 shares at $20.67 ($70,436)
- Chief Scientific Officer acquired 8,957 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Hansen Gwenn · Chief Scientific Officer
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-07-30 | Exercise or conversion : show line 1 in the form | +3,207 | 42,808 | D | ||
| 2024-07-30 | Exercise or conversion : show line 2 in the form | +2,000 | 44,808 | D | ||
| 2024-07-30 | Exercise or conversion : show line 3 in the form | +3,750 | 48,558 | D | ||
| 2024-07-30 | Sale : show line 4 in the form | −3,408 | $20.67 | $70,436 | 45,150 | D |
| Open-market sales · 3,408 sh · avg $20.67 · $70,436 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2024-07-30 | Exercise or conversion : show line 5 in the form Restricted Stock Units | −3,207 | 19,241 | D |
| 2024-07-30 | Exercise or conversion : show line 6 in the form Restricted Stock Units | −2,000 | 14,000 | D |
| 2024-07-30 | Exercise or conversion : show line 7 in the form Restricted Stock Units | −3,750 | 41,250 | D |
Loading xslF345X05/wk-form4_1722380775.xml…